Loading organizations...
WILD Group provides contract development and production for optomechatronic systems, offering end-to-end solutions from design to serial manufacturing. They precisely integrate optics, mechanics, and electronics, creating high-precision assemblies for micro and nano applications. This technical prowess enables delivery of integrated solutions that meet exacting industry standards.
Founded in 1970, WILD Group established a foundational legacy rooted in precision manufacturing. Its five-decade market presence highlights a commitment to stability, continuous innovation, and operational resilience. This extensive history underscores a deep engineering pedigree, consistently enabling high-quality delivery in demanding technological environments.
WILD Group partners with clients in medical, life sciences, laboratory, in-vitro diagnostics, laser, and semiconductor industries, serving as a trusted outsourced specialist. Their vision focuses on translating advanced innovations into dependable serial products. They aim to be a leading optomechatronic solutions provider, continuously evolving capabilities for future technological advancements.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Aug 19, 2020 | Bloom Diagnostics | $11.9M Series B | Thomas Pfisterer | — |
| Jul 31, 2019 | Sermonix Pharmaceuticals | $26.0M Series A | Thomas Pfisterer | Anthony Wild, Lodewijk de Vink, Richard DeSchutter |
| Oct 23, 2017 | ADC Therapeutics | $200.0M Other Equity | AstraZeneca, Auven Therapeutics, Redmile Group, Wild Family Office | — |
| Oct 27, 2016 | ADC Therapeutics | $105.0M Other Equity | — | AstraZeneca, Peter Corr, Wild Family Office |
